5
ALL5
AFT PharmaceuticalsYear
5
ALL2
20233
2021DEALS // DEV.
5
ALL5
DealsCountry
5
ALL1
FRANCE1
INDIA3
NEW ZEALAND5
ALL1
Crossject1
Hikma Pharmaceuticals1
Quoin Pharmaceuticals1
Salus Pharmaceuticals1
Timber PharmaceuticalsTherapeutic Area
5
ALL1
Dermatology3
Neurology1
Rare Diseases and DisordersStudy Phase
5
ALL3
Approved1
Phase II1
PreclinicalDeal Type
5
ALL5
Licensing AgreementProduct Type
5
ALL5
Small moleculeDosage Form
5
ALL1
Infusion1
Injectable/Injection1
Intravenous Injection1
Lotion1
TopicalLead Product
5
ALL1
Midazolam2
Paracetamol1
QRX0031
SirolimusTarget
3
ALL1
COX-11
Serine protease1
mTORDetails : Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Brand Name : Zeneo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Salus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries
Details : Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.
Brand Name : Maxigesic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Salus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003, a potential treatment for Netherton Syndrome in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
Brand Name : QRX003
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2021
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot ta...
Brand Name : Combogesic IV
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 28, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.
Brand Name : Pascomer
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 17, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?